soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo soul trial oral semaglutide cardiovascular

Their effects likely arise from a convergence of pathways: indirectly, through systemic improvements in glycemic control and metabolism, and directly, via the activation of intraocular GLP-1Rs on cells like retinal Mller and ganglion cells, which triggers local anti-inflammatory, anti-oxidant, and anti-apoptotic responses

Type of study: non-rct in vitro Number of citations: 80 Year: 1994 Authors: G

Post-mortem analysis of the prefrontal cortex showed significantly increased levels of 8-OH-Gua (see also above) which may in turn affect the aggregation of proteins (Balmus et al

You can naturally find this peptide in your blood, saliva, and tissues